Edoardo Camenzind

Summary

Publications

  1. ncbi Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implan
    Edoardo Camenzind
    Cardiology Department, University Hospital, Geneva, Switzerland
    Am Heart J 158:902-909.e5. 2009
  2. ncbi Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial
    Edoardo Camenzind
    University of Geneva, Switzerland
    Lancet 380:1396-405. 2012
  3. ncbi Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern
    Edoardo Camenzind
    University of Geneva, 1 rue Michel-Servet, 1211 Geneva, Switzerland
    Circulation 115:1440-55; discussion 1455. 2007
  4. ncbi Coronary myocardial bridge: an innocent bystander?
    Robert F Bonvini
    Cardiology Center, University Hospital of Geneva, 24 Rue Micheli du Crest, 1211 Geneva, Switzerland
    Heart Vessels 23:67-70. 2008
  5. ncbi Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro
    Anne C Brisset
    Department of Pathology and Immunology, University of Geneva, Switzerland
    Circ Res 100:1055-62. 2007
  6. ncbi Subendocardial calcification leading to the fortuitous discovery of a rare coronary anomaly
    Thomas Christen
    Division of Cardiology, University Hospital Geneva, Geneva, Switzerland
    Clin Cardiol 29:374. 2006
  7. ncbi High-risk left main coronary stenting supported by percutaneous left ventricular assist device
    Robert Francis Bonvini
    Cardiology Department, University Hospital of Geneva, Geneva, Switzerland
    Catheter Cardiovasc Interv 66:209-12. 2005
  8. ncbi Site-specific intracoronary delivery of octreotide in humans: a pharmacokinetic study to determine dose-efficacy in restenosis prevention
    Edoardo Camenzind
    Cardiac Catheterization Laboratory, University of Geneva, Switzerland
    J Cardiovasc Pharmacol 43:133-9. 2004
  9. ncbi Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial
    Patrick W Serruys
    Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    Circulation 109:627-33. 2004
  10. ncbi Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial
    Anthony Gershlick
    Department of Cardiology, University Hospitals of Leicester, Glenfield Hospital, Leicester, UK
    Circulation 109:487-93. 2004

Collaborators

Detail Information

Publications14

  1. ncbi Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implan
    Edoardo Camenzind
    Cardiology Department, University Hospital, Geneva, Switzerland
    Am Heart J 158:902-909.e5. 2009
    ..This large, international, randomized, controlled trial will provide important information on comparative rates of stent thrombosis between 2 different DES systems and safety as assessed by patient-relevant long-term clinical outcomes...
  2. ncbi Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial
    Edoardo Camenzind
    University of Geneva, Switzerland
    Lancet 380:1396-405. 2012
    ....
  3. ncbi Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern
    Edoardo Camenzind
    University of Geneva, 1 rue Michel-Servet, 1211 Geneva, Switzerland
    Circulation 115:1440-55; discussion 1455. 2007
  4. ncbi Coronary myocardial bridge: an innocent bystander?
    Robert F Bonvini
    Cardiology Center, University Hospital of Geneva, 24 Rue Micheli du Crest, 1211 Geneva, Switzerland
    Heart Vessels 23:67-70. 2008
    ....
  5. ncbi Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro
    Anne C Brisset
    Department of Pathology and Immunology, University of Geneva, Switzerland
    Circ Res 100:1055-62. 2007
    ..It is also a marker of a large population of human atheromatous and restenotic SMCs. Clarifying S100A4 function might be useful to understand the evolution of atherosclerotic and restenotic processes...
  6. ncbi Subendocardial calcification leading to the fortuitous discovery of a rare coronary anomaly
    Thomas Christen
    Division of Cardiology, University Hospital Geneva, Geneva, Switzerland
    Clin Cardiol 29:374. 2006
  7. ncbi High-risk left main coronary stenting supported by percutaneous left ventricular assist device
    Robert Francis Bonvini
    Cardiology Department, University Hospital of Geneva, Geneva, Switzerland
    Catheter Cardiovasc Interv 66:209-12. 2005
    ..This case illustrates a successful distal left main coronary artery V-stenting supported by the Tandem Heart in a patient with severe left ventricular dysfunction, severe aortic stenosis, and refractory myocardial ischemia...
  8. ncbi Site-specific intracoronary delivery of octreotide in humans: a pharmacokinetic study to determine dose-efficacy in restenosis prevention
    Edoardo Camenzind
    Cardiac Catheterization Laboratory, University of Geneva, Switzerland
    J Cardiovasc Pharmacol 43:133-9. 2004
    ..This approach is proposed for the determination of the appropriate site-specific coronary infusion dose for the inhibition of restenosis after balloon angioplasty...
  9. ncbi Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial
    Patrick W Serruys
    Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    Circulation 109:627-33. 2004
    ..We used serial intravascular ultrasound (IVUS) to prospectively analyze vessel responses in adjacent reference segments after implantation of polymer-controlled paclitaxel-eluting stents...
  10. ncbi Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial
    Anthony Gershlick
    Department of Cardiology, University Hospitals of Leicester, Glenfield Hospital, Leicester, UK
    Circulation 109:487-93. 2004
    ..CONCLUSIONS: Paclitaxel applied directly to the abluminal surface of a bare metal coronary stent, at a dose density of 2.7 microg/mm2, reduced angiographic indicators of in-stent restenosis without short- or medium-term side effects...
  11. ncbi An Internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation
    Roxana Mehran
    Cardiovascular Research Foundation, New York, NY 10022, USA
    Am Heart J 150:1171-6. 2005
    ..Heparin coating is an attractive alternative to counterbalance intrinsic stent thrombogenicity and to decrease the incidence of stent thrombosis...
  12. ncbi Treatment of in-stent restenosis--back to the future?
    Edoardo Camenzind
    N Engl J Med 355:2149-51. 2006
  13. ncbi DES, not always the best!
    Stéphane Zaza
    Crit Care Med 32:2166; author reply 2166. 2004
  14. ncbi Comparison of neointimal formation in polymer-free paclitaxel stents versus stainless stents (from the ASPECT and ELUTES randomized clinical trials)
    Grzegorz L Kałuza
    The Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiol 94:199-201. 2004
    ..05). Also, significantly shorter lesion lengths at 6-month follow-up were observed for the doses of 0.7 to 3.1 microg/mm(2) (p <0.03) relative to their respective lengths before the procedure compared with control stents...